The majority of RD and IBD patients switched from their index TNFα inhibitor to a second TNFα inhibitor (76.6% and 74.3%); most psoriasis patients switched to ustekinumab (64.7%), as shown in Figure 2A–C. Here, TNF is linked to inflammatory bowel disease.